摘要
目的探讨局部介入联合卡瑞利珠单抗与阿帕替尼治疗转移性软组织肉瘤的安全性与有效性。方法选取2019年3月至2020年6月收治的15例转移性软组织肉瘤患者,于局部介入后行卡瑞利珠单抗联合阿帕替尼治疗,采用Kaplan-Meier法绘制生存曲线,统计患者中位总生存期(mOS)、中位无进展生存期(mPFS)。临床疗效评估根据改良实体瘤评价标准(mRECIST),计算客观缓解率(ORR)、临床受益率(CBR)、临床获益持续时间(DoCB)并随访观察安全性。结果15例患者中1例CR、5例PR、7例SD、2例PD,mOS为14.9个月、mPFS为7.8个月、中位DoCB为8.4个月,ORR为40%,CBR为86.7%。Ⅲ级不良反应为贫血2例、高血压2例和白细胞减少1例,未观察到Ⅳ级不良反应。结论局部介入联合卡瑞利珠单抗与阿帕替尼能够显著延长转移性软组织肉瘤患者的生存期,且安全可控。
Objective To discuss the safety and curative effectiveness of local intervention combined with camrelizumab and apatinib in the treatment of metastatic soft tissue sarcoma(STS).Methods A total of 15 patients with metastatic STS,who were admitted to authors’hospital between March 2019 and June 2020,were enrolled in this study.All the patients received local intervention with subsequent camrelizumab and apatinib therapy.Kaplan-Meier method was used to draw the survival curve,and the median overall survival(mOS)and median progression-free survival(mPFS)of the patients were calculated.Based on the modified response evaluation criteria in solid tumors(mRECIST)the objective response rate(ORR),clinical benefit rate(CBR)and duration of clinical benefit(DoCB)were calculated.All the patients were regularly followed up to observe the clinical safety of the treatment.Results Of the 15 patients,complete respense(CR)was achieved in one,partial respense(PR)in 5,stable disease(SD)in 7,and progressive disease in 2.The mOS,mPFS and median DoCB were 14.9 months,7.8 months and 8.4 months respectively.The ORR and CBR were 40%and 86.7%respectively.GradeⅢadverse reactions included anemia(13.3%),hypertension(13.3%)and leukopenia(6.7%).No gradeⅣadverse reactions were observed.Conclusion For the treatment of metastatic STS,local intervention combined with camrelizumab and apatinib is clinically safe and it can significantly prolong the survival of patients.
作者
李岩
黎海亮
陈呈世
胡鸿涛
赵妍
LI Yan;LI Hailiang;CHEN Chengshi;HU Hongtao;ZHAO Yan(Department of Minimally-Invasive Intervention,Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou,Henan Province 450008,China)
出处
《介入放射学杂志》
CSCD
北大核心
2021年第11期1123-1127,共5页
Journal of Interventional Radiology
